医学知识

订阅

MedSci主页 / 所有栏目 / 医学知识

NHS支持Zykadia作为一线肺癌药物

2018-01-25 MedSci MedSci原创

一线肺癌药物Zykadia
关注

最后的指导方针已公布，NHS支持诺华公司的Zykadia作为ALK-阳性非小细胞肺癌(NSCLC)的一线用药，为患者提供一种新的治疗方案。临床试验显示服用Zykadia（西替替尼）的患者与服用化疗药物的患者的疾病进展风险降低45％。接受一线Zykadia治疗的患者的中位无进展生存期（PFS）为16.6个月，而采用标准一线培美曲塞-铂化疗方案维持治疗的患者的中位无进展生存期为8.1个月。该药也显示脑


最后的指导方针已公布，NHS支持诺华公司的Zykadia作为ALK-阳性非小细胞肺癌(NSCLC)的一线用药，为患者提供一种新的治疗方案。

临床试验显示服用Zykadia（西替替尼）的患者与服用化疗药物的患者的疾病进展风险降低45％。

接受一线Zykadia治疗的患者的中位无进展生存期（PFS）为16.6个月，而采用标准一线培美曲塞-铂化疗方案维持治疗的患者的中位无进展生存期为8.1个月。

该药也显示脑转移患者的中位PFS为10.7个月，而化疗组为6.7个月。

国家健康和护理研究所得出的结论是，除了临床效益，Zykadia还提供国民保健服务的价值。

考虑到患者的隐私，Zykadia的增量成本效益比率与辉瑞公司的Xalkori（crizotinib）相比，每个质量调整生命年（QALY）增加20，000到30，000英镑，低于最大阈值。


此文系梅斯医学（MedSci)原创整理编译，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1638367, encodeId=5d5e163836ec7, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun May 27 21:29:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285472, encodeId=18ad2854e2ba, content=学习了.谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIxvMP6OXzUiaGH5MkDQlW0hczROZxec1gZjfZ52EtN6aG9t0uDZq2A5xmf9FWMa4tZib4qoYnledFg/132, createdBy=9d6c2167401, createdName=hanmeijinxiu, createdTime=Mon Feb 05 22:53:35 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515258, encodeId=37a9151525882, content=<a href='/topic/show?id=402a12e83da' target=_blank style='color:#2F92EE;'>#NHS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12783, encryptionId=402a12e83da, topicName=NHS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=626110750337, createdName=小几洁, createdTime=Sat Jan 27 13:29:00 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282077, encodeId=507d2820e770, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Jan 26 02:43:21 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282041, encodeId=5f9828204128, content=最后的指导方针已公布.NHS支持诺华公司的Zykadia作为ALK-阳性非小细胞肺癌(NSCLC)的一线用药.为患者提供一种新的治疗方案., beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Thu Jan 25 23:26:31 CST 2018, time=2018-01-25, status=1, ipAttribution=)]
    2018-05-27 ms9608593228839890

    #DIA#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1638367, encodeId=5d5e163836ec7, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun May 27 21:29:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285472, encodeId=18ad2854e2ba, content=学习了.谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIxvMP6OXzUiaGH5MkDQlW0hczROZxec1gZjfZ52EtN6aG9t0uDZq2A5xmf9FWMa4tZib4qoYnledFg/132, createdBy=9d6c2167401, createdName=hanmeijinxiu, createdTime=Mon Feb 05 22:53:35 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515258, encodeId=37a9151525882, content=<a href='/topic/show?id=402a12e83da' target=_blank style='color:#2F92EE;'>#NHS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12783, encryptionId=402a12e83da, topicName=NHS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=626110750337, createdName=小几洁, createdTime=Sat Jan 27 13:29:00 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282077, encodeId=507d2820e770, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Jan 26 02:43:21 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282041, encodeId=5f9828204128, content=最后的指导方针已公布.NHS支持诺华公司的Zykadia作为ALK-阳性非小细胞肺癌(NSCLC)的一线用药.为患者提供一种新的治疗方案., beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Thu Jan 25 23:26:31 CST 2018, time=2018-01-25, status=1, ipAttribution=)]
    2018-02-05 hanmeijinxiu

    学习了.谢谢!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1638367, encodeId=5d5e163836ec7, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun May 27 21:29:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285472, encodeId=18ad2854e2ba, content=学习了.谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIxvMP6OXzUiaGH5MkDQlW0hczROZxec1gZjfZ52EtN6aG9t0uDZq2A5xmf9FWMa4tZib4qoYnledFg/132, createdBy=9d6c2167401, createdName=hanmeijinxiu, createdTime=Mon Feb 05 22:53:35 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515258, encodeId=37a9151525882, content=<a href='/topic/show?id=402a12e83da' target=_blank style='color:#2F92EE;'>#NHS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12783, encryptionId=402a12e83da, topicName=NHS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=626110750337, createdName=小几洁, createdTime=Sat Jan 27 13:29:00 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282077, encodeId=507d2820e770, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Jan 26 02:43:21 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282041, encodeId=5f9828204128, content=最后的指导方针已公布.NHS支持诺华公司的Zykadia作为ALK-阳性非小细胞肺癌(NSCLC)的一线用药.为患者提供一种新的治疗方案., beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Thu Jan 25 23:26:31 CST 2018, time=2018-01-25, status=1, ipAttribution=)]
    2018-01-27 小几洁

    #NHS#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1638367, encodeId=5d5e163836ec7, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun May 27 21:29:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285472, encodeId=18ad2854e2ba, content=学习了.谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIxvMP6OXzUiaGH5MkDQlW0hczROZxec1gZjfZ52EtN6aG9t0uDZq2A5xmf9FWMa4tZib4qoYnledFg/132, createdBy=9d6c2167401, createdName=hanmeijinxiu, createdTime=Mon Feb 05 22:53:35 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515258, encodeId=37a9151525882, content=<a href='/topic/show?id=402a12e83da' target=_blank style='color:#2F92EE;'>#NHS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12783, encryptionId=402a12e83da, topicName=NHS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=626110750337, createdName=小几洁, createdTime=Sat Jan 27 13:29:00 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282077, encodeId=507d2820e770, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Jan 26 02:43:21 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282041, encodeId=5f9828204128, content=最后的指导方针已公布.NHS支持诺华公司的Zykadia作为ALK-阳性非小细胞肺癌(NSCLC)的一线用药.为患者提供一种新的治疗方案., beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Thu Jan 25 23:26:31 CST 2018, time=2018-01-25, status=1, ipAttribution=)]
    2018-01-26 三生有幸9135

    学习一下谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1638367, encodeId=5d5e163836ec7, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun May 27 21:29:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285472, encodeId=18ad2854e2ba, content=学习了.谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIxvMP6OXzUiaGH5MkDQlW0hczROZxec1gZjfZ52EtN6aG9t0uDZq2A5xmf9FWMa4tZib4qoYnledFg/132, createdBy=9d6c2167401, createdName=hanmeijinxiu, createdTime=Mon Feb 05 22:53:35 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515258, encodeId=37a9151525882, content=<a href='/topic/show?id=402a12e83da' target=_blank style='color:#2F92EE;'>#NHS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12783, encryptionId=402a12e83da, topicName=NHS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=626110750337, createdName=小几洁, createdTime=Sat Jan 27 13:29:00 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282077, encodeId=507d2820e770, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Jan 26 02:43:21 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282041, encodeId=5f9828204128, content=最后的指导方针已公布.NHS支持诺华公司的Zykadia作为ALK-阳性非小细胞肺癌(NSCLC)的一线用药.为患者提供一种新的治疗方案., beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Thu Jan 25 23:26:31 CST 2018, time=2018-01-25, status=1, ipAttribution=)]
    2018-01-25 有备才能无患

    最后的指导方针已公布.NHS支持诺华公司的Zykadia作为ALK-阳性非小细胞肺癌(NSCLC)的一线用药.为患者提供一种新的治疗方案.

    0